Abstract
Objective: The objective of this study is to point out at the risk of cardiotoxicity of anticancer treatment in ovarian cancer patients. Patients and Methods: The study included 55 patients treated for epithelial ovarian cancer newly diagnosed in the period 7/2013-11/2015.
Biochemical cardiotoxicity markers (NT-proBNP, cTnT, TnI, CK-MB, MYO, h-FABP, GPBB), echocardiography and electrocardiography were evaluated during primary anticancer treatment.Results: Chemotherapy with paclitaxel and carboplatin has an impact on the QT interval and its dispersion. Concentrations of FABP, troponin T and NT-proBNP increased with the total dose of first line cytostatic agents.
We found elevated CK-myoglobin (P = 0.051) and troponin T (P = 0.53) especially in ovarian cancer patients after the administration of ten cycles of chemotherapy with paclitaxel and carboplatin and bevacizumab in comparison with ovarian cancer patients receiving standard chemotherapy only. Conclusion: Cardiac toxicity is one of the possible adverse events of oncology treatment.
It is an interdisciplinary issue requiring close cooperation between the oncologist, cardiologist and specialist in clinical biochemistry. Therefore special attention should be paid to prevent cardiac damage or at least to its early identification and prompt treatment.